ROS Therapeutics Holding ApS: Financial statements 2022
CVR: 39507056
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
ROS Therapeutics Holding ApS (CVR 39507056) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -12,500 and a net result of DKK -13,879 compared with DKK -4,284,829 the year before. Equity in the 2022 report amounted to DKK -229,117. The company had 1 employee in the financial year.
- Gross Profit
- DKK -12,500
- Profit/Loss
- DKK -13,879
- Equity
- DKK -229,117
- Total Assets
- DKK 34,689
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -13K | -14K | -229K | 1 |
| 2021 | - | -13K | -4.3M | -225K | 1 |
| 2020 | - | -13K | 4M | 4.1M | 1 |
| 2019 | - | -15K | -12K | 66K | 1 |
Official annual report
Keep an eye on ROS Therapeutics Holding ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
ROS Therapeutics Holding ApS has published its annual report for 2021. Gross profit came to DKK -12,500, and the net result was DKK -4,284,829.
About ROS Therapeutics Holding ApS
ROS Therapeutics Holding ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Hanne Damgaard Jensen. The company is owned by SPORCON LIFESCIENCE ADVISORS ApS and HDJ & LEJ Invest ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -10,750 and a net result of DKK -26,512 compared with DKK -14,342 the year before. Equity in the 2025 report amounted to DKK -116,804.
